Company: BSX
Filing Date: 2025-02-24
Form Type: 424B2
Source: 0001104659-25-016521
Chunk: 1

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-24
Form: 424B2
Chunk 1
---
 subordinated to the notes. All of AMS Europe’s obligations under the notes will be fully and unconditionally guaranteed by Boston Scientific, AMS Europe’s ultimate parent company, on a senior unsecured basis (the “guarantees”). The guarantees will rank equally in right of payment with all of Boston Scientific’s other existing and future unsecured and unsubordinated indebtedness and be senior to any future indebtedness of Boston Scientific that is subordinated to the guarantees. The notes and the guarantees will be effectively junior to any future secured indebtedness of AMS Europe and Boston Scientific, respectively, to the extent of the collateral securing such indebtedness, and be structurally junior to any existing and future indebtedness and other liabilities of Boston Scientific’s subsidiaries (other than AMS Europe). Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the notes or determined that this prospectus supplement and the accompanying prospectus are accurate or complete. Any representation to the contrary is a criminal offense. Currently, there is no public market for the notes. Application will be made for the notes to be admitted to the Official List of the Irish Stock Exchange plc, trading as Euronext Dublin (“Euronext Dublin”), and to trading on the Global Exchange Market thereof. The Global Exchange Market is not a regulated market within the meaning of Directive 2014/65/EU (as amended, “MiFID II”). There can be no assurance that the notes will be admitted to the Official List of Euronext Dublin or admitted to trading on the Global Exchange Market. The listing application will be subject to approval by Euronext Dublin. AMS Europe currently expects the notes to be admitted to the Official List of Euronext Dublin and to trading on the Global Exchange Market within 30 days after the original issue date. Investing in our securities involves risks. See “Information Concerning Forward-Looking Statements” on page S-12 and the risks described under the heading “Risk Factors” beginning on page S-6of this prospectus supplement and under the heading “Risk Factors” in our periodic reports that we file with the Securities and Exchange Commission before investing in any of our securities.

| ​                | ​ | ​ | Offering Priceto Public(1) |   |               |   | ​ | ​ | UnderwritingDiscounts |   |           |   | ​ | ​ | Proceeds to AMS EuropeBefore Expenses |   |               |   | ​ |
| Per 2031 Note    | ​ | ​ | ​                          | ​